MoonLake Immunotherapeutics' 10-K Item 1C cybersecurity disclosure describes the company's cybersecurity risk management program, governance, and Board/Audit Committee oversight. The filing explicitly states that in the last fiscal year no cybersecurity incidents have materially affected the company. No specific breach, incident, threat actor, affected individual count, or compromised data is disclosed.